J&J Forecasts 25 Blockbuster Drugs to Drive Sales Growth Through 2030

Dec 06, 2023 12:10 CST Updated 12:10

Johnson & Johnson

Healthcare Product Manufacturers, Health Service Providers

On December 5, 2023, Johnson & Johnson conducted the 2023 Enterprise Business Review and announced the key drivers for the company's long-term competitive growth.

Johnson & Johnson is shifting its focus toIn the fields of cancer, depression, and autoimmune diseases. The company released its long-term sales outlook,It is expected that the operating sales in 2024 will increase by 5%.-6%, and this year's growthExpected to be 8.5%-9%，The compound annual growth rate from 2025 to 2030 is 5%-7%.。

In thisIn the enterprise business assessment, Johnson & Johnson listed its expectations for 2025.-Expectations for 2030. It indicates,CompanyPlan to provide more than 20 new drugs and over 50 product expansions by 2030。

10 or more drugsPeak sales potential of at least $5 billion, includingIts 2021 "Pharmaceutical Business Review》The five assets emphasized in TALVEY, TECVAYLI, and JNJ-2113。
15 Products with Sales Potential of $10-50 Billion, including SPRAVATO, seltorexant, aticaprant, and JNJ-4804etc.

Notably, this forecast is based on drugs currently in development and excludes any potential deals.

By 2030, Johnson & Johnson aims to be at the forefront of the industry in multiple fields. The company believes that by the end of this decade,It is expected to become the top player in the fields of oncology, neuroscience, and immunology. Among them,Oncology will become Johnson & Johnson's top therapeutic area, said Jennifer Taubert, Executive Vice President of Johnson & Johnson Pharmaceuticals, during a business review.In the broader field of oncology,The company should launch approximately 2 new therapies each year in the next few years.。

Moreover, the company is highly confident in its multiple myeloma product portfolio, believing it has the potential to transform the treatment landscape.The potential of the game rules, including drugs such as Talvey and CAR-T Carvykti. The company is developing strategies and combinations to "redefine the future of how we treat this disease."ItsGlobal Head of Oncology Therapeutics, Peter LebowitzRepresentation.

Based on this, Johnson & JohnsonBiljana Naumovic, Vice President of Global Commercial Strategy Oncology, addedJohnson & Johnson's goal in the multiple myeloma treatment field is to have a treatment option for every line in this area by the end of this century.Become "the only pharmaceutical company with a full range of products"。

Meanwhile, in the field of immunology, the company's product line spans multiple areas from ulcerative colitis to Crohn's disease.

In neuroscience, the company will keep up with the growing market demand. To achieve this, the company plans to identify disease subtypes and predict which patients will respond best to specific drugs.Johnson & Johnson stated thatPlanned for submission in 2030Six applications, five of which are top performers in the same product category.

It can be said that Johnson & JohnsonJohnson & Johnson is confident in its growth prospects, even though the company will lose patent protection for its psoriasis blockbuster product Stelara in Europe next year, and generic competitors will also enter the European market. Nevertheless, Johnson & Johnson still forecasts its revenue to grow by 5%-6% in 2024.

In additionIn the United States, Johnson & Johnson has delayed the entry of Stelara biosimilars by reaching a series of patent settlements with companies such as Amgen, Alvotech, and Teva.By 2025.

It is reported that Stelara has been approved for the treatment of psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. Since its launch, it has consistently ranked as Johnson & Johnson’s top-selling drug. In 2022, the drug generated sales of $9.7 billion; in the third quarter of 2023, it accounted for one-fifth of the company’s pharmaceutical revenue.

References:

[1]J&J Expects Up to 6% Growth Next Year with 20-Plus New Drugs by 2030.BioSpace.Published: Dec 05, 2023 By Kate Goodwin.

[2]UPDATED: As Stelara cliff looms, J&J expects 25 blockbuster drugs to drive future sales growth.Firece Pharma.By Fraiser KansteinerDec 5, 2023 4:42pm.

[3] Johnson & Johnson Official Website.

Scan the WeChat QR code to add.Medicine Space-TimeEditor

Please indicate: Name + Research Direction!